top of page
VascVersa attend the International Society for Cell & Gene Therapy 2024
JUNE 24

VascVersa attend the International Society for Cell & Gene Therapy 2024

Both Christina and Stuart were delighted to attend ISCT 2024 in Vancouver. It was fantastic to have the opportunity to connect with experts in the cell and gene therapy field and ...

Christina takes part in Region City Deal roundtable discussion
JUNE 24

Christina takes part in Region City Deal roundtable discussion

Christina represented VascVersa at the panel discussion. It was great to showcase VascVersa and give the audience an insight into...

Fiona wins a C-TRIC funding competition
MAY 24

Fiona wins a C-TRIC funding competition

Fiona was successful in her application for the C-TRIC single-cell competition. Winning this competition funds a multiomic analysis study worth £10K...

Christina attends EWMA Conference in London.
MAY 24

Christina attends EWMA Conference in London.

Christina was delighted to attend the European Wound Management Association (EWMA) conference in London. This was an excellent conference featuring...

Fiona presents Angicyte Technology at Scotblood 2024
MAY 24

Fiona presents Angicyte Technology at Scotblood 2024

Fiona represented VascVersa at the annual Scotblood conference held at the beautiful University of Stirling.

VascVersa secures Launchpad NI funding
MAY 24

VascVersa secures Launchpad NI funding

VascVersa are pleased to announce their success in securing Launchpad NI funding. This funding will allow VascVersa to...

VascVersa showcased at HealthTech Spring
APRIL 2024

VascVersa showcased at HealthTech Spring

This event hosted by HIRANI was held in the beautiful Titanic Building in Belfast in April 2024. It brought together key stakeholders in digital ecosystems, diagnostics and therapeutics...

VascVersa present at the Advanced Therapies 2024
MARCH 2024

VascVersa present at the Advanced Therapies 2024

VascVersa attended Advanced Therapies 2024 in London. This event is Europe’s largest commercial cell and gene therapy conference and exhibition....

VascVersa takes part in the NI Deep Tech Summit 2023
NOVEMBER 2023

VascVersa takes part in the NI Deep Tech Summit 2023

VascVersa took part in the NI Deep Tech Accelerator Programme and presented at the DeepTech Summit in Belfast -November 2023

VascVersa presents at the Inbound Investors
SEPTEMBER 2023

VascVersa presents at the Inbound Investors

Christina presented at Inbound Investors. Inbound Investors took place at the Titanic Hotel in Belfast...

VascVersa collaborates with Hitech Health
AUGUST 2023

VascVersa collaborates with Hitech Health

VascVersa is delighted to partner with HiTech Health, Galway....

VascVersa secure Invest NI funding
JULY 2023

VascVersa secure Invest NI funding

VascVersa have been awarded Invest NI funding. This support from Invest NI will allow us to strengthen our Angicyte portfolio...

VascVersa completes the setup of Specialised Lab Space
JUNE 2023

VascVersa completes the setup of Specialised Lab Space

Working alongside QUBIS, VascVersa has now moved into a fully operational lab suite comprised of a spacious, main laboratory and two satellite tissue culture suites.

VascVersa partners with Alcyomics
MAY 2023

VascVersa partners with Alcyomics

VascVersa is delighted to work with Alcyomics. The Newcastle based company are highly experienced experts in determining the safety of therapeutic products including advanced cellular therapies.

VascVersa Recruits New Scientist
SEPTEMBER 2022

VascVersa Recruits New Scientist

VascVersa is pleased to announce the addition of Dr Fiona Cunningham to the team!

VascVersa completes second investment round
AUGUST 2022

VascVersa completes second investment round

VascVersa completes second investment round to accelerate development of ground-breaking cell therapies.

VascVersa proudly working with Anthony Nolan charity
MARCH 2022

VascVersa proudly working with Anthony Nolan charity

VascVersa will work with Anthony Nolan Cell & Gene Therapy Services who will support the company by supplying high-quality cord material for VascVersa to facilitate their development of ANGICYTE™ technology.

VascVersa Pitched at HBAN Ulster Investor Meeting
MARCH 2022

VascVersa Pitched at HBAN Ulster Investor Meeting

This face to face event supported by Clarendon Fund Managers provided a fantastic opportunity for the team to showcase ANGICYTE™ technology to a local investor network. VascVersa presented...

Successful Biomedical Catalyst Funding Award
FEBRUARY 2022

Successful Biomedical Catalyst Funding Award

VascVersa leads consortium to advance new cell therapy for the treatment of chronic non-healing wounds.

Intertrade Ireland Seedcorn Regional Finalists 2021
SEPTEMBER 2020

Intertrade Ireland Seedcorn Regional Finalists 2021

VascVersa reach regional finals in Intertrade Ireland Seedcorn Competition 2021. This Seedcorn investor readiness competition was a fantastic opportunity for the company to secure expert feedback...

Vascversa participated in 2021 Pulse event
MARCH 2021

Vascversa participated in 2021 Pulse event

VascVersa were awarded a place on a prestigious PULSE programme. This was a three-day leadership and entrepreneurship training programme developed by the BIA and the Francis Crick Institute.

NI’s First Cell Therapy Company Secure Six Figure Deal
APRIL 2021

NI’s First Cell Therapy Company Secure Six Figure Deal

Award winning Queen’s University spin out VascVersa has completed a six-figure deal in its first investment round led by QUBIS, with support from Co-Fund NI and a group of angel investors from...

VascVersa attend Cell & Gene at the Abbey conference, Galway
NOVEMBER 2021

VascVersa attend Cell & Gene at the Abbey conference, Galway

VascVersa were excited to attend their first face to face event in 2021 at the beautiful Glenlo Abbey in Galway. This event hosted by HiTech Health was a three-day event featuring international experts...

VascVersa join the NA-ATCC
DECEMBER 2021

VascVersa join the NA-ATCC

VascVersa were delighted to become an NA-ATCC partner. The consortium consists of twenty industry, NHS and academic organisations lead by...

News

bottom of page